-
Study aim
-
The effect of melatonin supplementation on calcitonin gene-related peptide (CGRP)and headache symptoms in women with migraine
-
Design
-
A randomized controlled clinical trial with parallel groups, double-blind, randomized
-
Settings and conduct
-
The present study is a double-blind, randomized, parallel clinical trial. The target population includes those with migraines referred to the khorshid Clinic and Imam Musa Sadr Clinic who are diagnosed according to the criteria of the International Headache Society (HIS) by a neurologist . Split and study for 8 weeks. Before and after the intervention, severity of headache, frequency of headache and duration of headache, serum CGRP level , depression, stress, anxiety and quality of life of migraine patients will be measured. To double-blind this study, all capsules were coded as A and B prior to study initiation.
-
Participants/Inclusion and exclusion criteria
-
Inclusion criteria: women from the age of 18 to before menopause; diagnosis of migraine by a neurologist; willingness to cooperate with the plan.
Exclusion criteria: people with a history of overdose of analgesics according to IHS criteria for antidepressant abuse; pregnancy or breast-feeding; history of significant complications or recent use of melatonin supplements; severe depression in the past year.
-
Intervention groups
-
Control group (n=44): one placebo (50 mg starch) half an hour before bedtime, 8 weeks.
Intervention group(n=44): Melatonin 3 mg half an hour before bedtime, 8 weeks.
-
Main outcome variables
-
Migraine severity score; migraine frequency; duration of migraine; CGRP inflammatory factor, depression, stress, anxiety, quality of life, weight, body mass index